<DOC>
	<DOCNO>NCT00146042</DOCNO>
	<brief_summary>This research study aim improve way doctor determine dose chemotherapy give patient . Right , chemotherapy determine patient 's height weight . However , patient metabolize chemotherapy fast slow average person different level drug metabolize enzyme liver . Therefore , patient either give small large dose chemotherapy amount enzyme take account . This research study examine use simple test , call Erythromycin Breath Test ( ERMBT ) determine amount enzyme metabolize chemotherapy drug docetaxel ( Taxotere ) . The dose docetaxel tailor amount enzyme available metabolize drug patient . The drug , docetaxel , combine another drug , trastuzumab ( Herceptin ) , time combination appear promising metastatic breast cancer research .</brief_summary>
	<brief_title>UMCC 9901 : Phase II Study Tailored-Dose Docetaxel + Trastuzumab Her-2 Positive Metastatic Breast Cancer</brief_title>
	<detailed_description>This research study aim improve way doctor determine dose chemotherapy give patient . Right , chemotherapy determine patient 's height weight . However , patient metabolize chemotherapy fast slow average person different level drug metabolize enzyme liver . Therefore , patient either give small large dose chemotherapy amount enzyme take account . This research study examine use simple test , call Erythromycin Breath Test ( ERMBT ) determine amount enzyme metabolize chemotherapy drug docetaxel ( Taxotere ) . The dose docetaxel tailor amount enzyme available metabolize drug patient . The drug , docetaxel , combine another drug , trastuzumab ( Herceptin ) , time combination appear promising metastatic breast cancer research.-Patients participate study biopsy proven , measurable metastatic breast cancer . During study : - Patients receive tailored-dose docetaxel Trastuzumab breast cancer . - There sex age restriction although patient disease category reflective adult female population . Approximately 30 subject recruit site . Diagnosis Staging • All patient primary tumor measurement physical exam and/or radiographic study ( CT , MRI , bone scan ) . Erythromycin Breath Test* • The ERMBT administer outpatient setting , prior first cycle docetaxel . Twenty minute injection trace amount ( 14C N-methyl ) erythromycin , ( This test assess activity cytochrome P450 enzyme largely responsible metabolism chemotherapeutic agent docetaxel . ) patient exhale tube create bubble solution hyamine hydroxide , ethanol , blue indicator 2 mmol carbon dioxide trap blue color vanishes . Chemotherapy Regimen Premedications - Dexamethasone 8 mg po bid three day , begin day prior docetaxel administration . - Diphenhydramine 50 mg IVPB - Granisetron 2 mg po 30 minute pre-docetaxel Chemotherapy - Docetaxel , tailor dose , infuse 1 hour day 1 every 3 week duration study . - Starting dose docetaxel determine ERMBT serum albumin accord formula state protocol ( page 11 ) . - Trastuzumab , 4 mg/kg infuse 90 minute day 2 ( pharmacokinetic sampling ) . - Beginning week 2 , trastuzumab give dose 2 mg/kg weekly throughout duration study . ( After first dose docetaxel , future dos may give day docetaxel ) . Suggested post-chemotherapy antiemetic : - Compazine 10 mg po q 6 hour prn nausea/vomiting Pharmacokinetic Analysis - All patient pharmacokinetic determination blood drawn pharmacokinetic analysis 24 hour period first docetaxel treatment . Time point include time 0 , 15 minute , 45 minute , 180 minute ( 3 hour ) , 390 minute ( 6.5 hour ) , 1440 minute ( 24 hour ) . DEXA Scan* - DEXA scan perform patient 's stay Clinical Research Center , Lunar DPXL Bone Densitometer . This simple noninvasive test use x-rays computer program analyze ratio 38 keV 70 keV attenuation . The program calculate Fat Lean value arm , leg , abdomen , rib , total body . This test widespread clinical use evaluation osteoporosis . During DEXA scan , patient expose trace amount radiation equal 2 % yearly background dose , less . *The amount radiation administer erythromycin breath test DEXA scan medically significant . - Patients receive 2 cycle docetaxel/trastuzumab re-evaluated response ( ever 6 week , later dosage delay cause lengthening cycle ) . - Responding stable patient continue receive docetaxel therapy , evaluation every 2 cycle ( every 6 week , later dosage delay cause lengthening cycle ) . - Continued treatment beyond 8 cycle discretion patient 's primary oncologist .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Erythromycin</mesh_term>
	<mesh_term>Erythromycin Estolate</mesh_term>
	<mesh_term>Erythromycin Ethylsuccinate</mesh_term>
	<mesh_term>Erythromycin stearate</mesh_term>
	<criteria>Patients biopsy proven , measurable metastatic breast cancer . Patients boneonly , and/or effusiononly disease exclude . HER2 neu positive standard immunohistochemical criterion ( 2+ positivity ) . No prior chemotherapy distant metastatic disease . Prior paclitaxel adjuvant setting allow . Karnofsky performance status equal 70 great . ANC &gt; 1500 , Hgb &gt; 10 , plt &gt; 100 . Patients degree hepatic dysfunction renal dysfunction encourage , order evaluate ability ERMBT tailor dose patient population . Age le 18 year . Allergy erythromycin . Previous treatment docetaxel . Prior paclitaxel allow . Grade &gt; 2 peripheral neuropathy . No confound factor present provide misinterpretation data ( i.e. , concurrent malignancy ) . Patients pregnant nursing eligible protocol . Women childbearing age practice reliable birth control must document negative serum HCG . Patients require concurrent treatment drug know induce inhibit CYP3A activity ineligible trial . This list include drug midazolam , antimycotic agent ( ketoconazole relate compound ) , macrolide antibiotic ( erythromycin relate compound ) , nifedipine , antiseizure drug , rifampin ( induction ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>